Compare THH & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THH | BNGO |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | Japan | United States |
| Employees | 116 | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 12.9M |
| IPO Year | N/A | 2018 |
| Metric | THH | BNGO |
|---|---|---|
| Price | $0.31 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 1.2M | 140.9K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000,735.00 |
| Revenue This Year | N/A | $14.99 |
| Revenue Next Year | N/A | $34.73 |
| P/E Ratio | $305.05 | ★ N/A |
| Revenue Growth | N/A | ★ 26.26 |
| 52 Week Low | $0.25 | $1.06 |
| 52 Week High | $56.26 | $5.50 |
| Indicator | THH | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 45.30 |
| Support Level | $0.28 | $1.13 |
| Resistance Level | $0.53 | $1.18 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 20.73 | 33.33 |
Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.